ArticleGenome medicine2025
Location and aetiology are determinants of fibroblast activation and heterogeneity in the failing human heart.
Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets.Nature reviews. Cardiology · 2026Review
- ParTIpy: a scalable framework for archetypal analysis and Pareto task inference.Molecular systems biology · 2026Article
- Dual relevance ofFrontiers in oncology · 2026Article
- Hypoxia-driven crosstalk among cardiac fibroblasts, macrophages, and endothelial cells in cardiac fibrosis.Frontiers in cell and developmental biology · 2026Review
- Location and aetiology are determinants of fibroblast activation and heterogeneity in the failing human heart.Genome medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCardiac fibrosis is a key feature of pathological cardiac remodelling that significantly impacts heart function through contributing to stiffness, diastolic dysfunction, and arrhythmias, ultimately leading to heart failure (HF). Despite extensive research into fibrosis-related matrix alterations, therapeutic advancements are limited, in part owing to the different nature (reparative vs interstitial) and tissue distribution of fibrosis involved. To identify unique features of fibrosis phenotypes, we investigated fibroblast (FB) heterogeneity and spatial distribution in left ventricular myocardium in HF patients with ischemic (ICM) and dilated cardiomyopathy (DCM). Infarct scar was also analysed.
methodsWe performed single-nucleus RNA sequencing of 20 human left ventricular tissue samples: from non-failing, NF (N = 4), DCM (N = 6) and ICM (N = 5) hearts, and from the ICM scar region (N = 5). The data was subjected to bioinformatic analysis, included clustering, differential expression, ligand-receptor inference, and pseudotime trajectory mapping to delineate FB transitions and regional fibrosis signatures. To identify localisations of FB states and cellular neighbourhoods, data was integrated with publicly available spatial transcriptomics datasets.
resultsWe identified distinct FB subpopulations across failing and non-failing hearts. Resident FB states showed preferential perivascular and interstitial distribution in NF and exhibited significant depletion in HF, giving rise to different disease states. We identified shared and unique activation ligands driving the onset of FB transitions as well as transcriptional differences between scar and interstitial fibrosis, and between ICM and DCM interstitial fibrosis. Trajectory analysis revealed distinct differentiation pathways for FB depending on its originating resident FB, with specific transcription factors guiding each transition.
conclusionsThese findings provide a comprehensive framework for understanding fibroblast dynamics, highlighting the heterogeneity and spatial complexity of fibrosis in human end-stage HF, and offering potential therapeutic targets to mitigate fibrosis while preserving scar integrity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.